10 Years of Transformation in Bone Marrow Transplantation | History of NYP | Advances in Oncology

Advances in CAR-T cell therapy

One of the biggest medical developments of the past decade is chimeric antigen receptor (CAR-T) cell therapy. This is a type of immunotherapy that manipulates T cells to recognize and attack cancer cells. “CAR-T cell therapy allows us to offer cellular immunotherapy to patients with blood cancers, solid tumors, and even autoimmune diseases,” says Dr. Mapala. It has revolutionized the treatment of two disease areas in particular: lymphoma and myeloma. Dr. Mapala said CAR-T cell therapy has been successful in treating some lymphoma patients who have not responded to standard treatments, and that BCMA (B-cell maturation antigen) CAR-T can contribute to long-term progression-free treatment. He said that Survival of myeloma populations.

The Irving Bone Marrow Transplant Unit's Cellular Immunotherapy Program Ran Reshef, MD, MScHe is the department's director of translational research, and he is researching CAR in adults with relapsed or persistent diffuse large B-cell lymphoma (DLBCL) and multiple myeloma patients, a common form of non-Hodgkin's lymphoma. -Provides T-cell therapy. The program is working to expand the treatment to patients with solid tumors as well as some autoimmune diseases and inflammatory conditions. To date, more than 130 CAR-T cell infusions have been performed and 28 patients have been treated with T-cell immunotherapy.

NewYork-Presbyterian and Columbia University also have the distinction of being one of the few facilities equipped to expand and manipulate T cells for patients with cancer and serious infections, a role typically The Pharmaceutical Research Institute is in charge of this. In 2017, the facility established a Cellular Immunotherapy Laboratory. Dr. Pawel MuranskiAs Director, we produce clinical-grade immune cells under the FDA's strict Current Good Manufacturing Practice (cGMP) guidelines.

The cGMP facility currently produces antigen-specific T cells based on a treatment protocol developed by Dr. Muranski to treat viral infections that are refractory to standard viral drugs or for which no antiviral drugs exist. I am doing it. This helps address issues common to solid organ and bone marrow transplant patients, Dr. Mapala explains. The protocol has been approved by the FDA and patients have recently begun enrolling for treatment.

New cellular immunotherapy approaches are also being developed. Dr. Mapala said one future goal is to engineer T cells used in cancer treatment to make them resistant to immunosuppressive drugs in transplant patients.